The Amazon Development Fund (FDA) is an important instrument of action of the National
Regional Development Policy (PNDR) in the Legal Amazon, being an inducer of large
productive enterprises for the region. Some conditions of its system may harm the Fund's
attractiveness to credit seekers in the region and financial institutions able to act as operating
agents. This work analyzes these conditions from normative, technical and project approval
aspects, using data extracted from FDA technical reports prepared by Sudam and technical
reports from Condel/SUDAM, PRDA and CGU. With this, the following research problem
arises: What aspects have a negative impact on the attractiveness of the FDA? The theoretical
framework addresses the main theories on regional development, the main government
interventions in terms of development in the Amazon, from the creation of SPVEA and
SUDAM in 1966 until their extinction in 2001 and recreation in 2007, in parallel with an
analysis of the funds that preceded the creation of the FDA, covering the main aspects of
governance and management and the main characteristics that differentiate them. Next, the
work analyzes the regulatory history that has guided the FDA's system since its creation,
detailing 5 operational difficulties listed based on the report data. As results, the work
presents a proposal to increase the remuneration of the operating agent associated with the
risk assumed, increase the maximum FDA financing limits, decrease the project contracting
period and indicate the establishment of a minimum percentage to be contributed annually by
the STN in the FDA.
|
